The Mycobacterium Tuberculosis Cytochrome P450 System

Overview

Journal Arch Biochem Biophys

Publisher Elsevier

Specialties Biochemistry
Biophysics

Date 2009 Jul 29

PMID 19635450

Citations 44

Authors

Hugues Ouellet

Jonathan B Johnston

Paul R Ortiz de Montellano

Affiliations

Soon will be listed here.

Abstract

Tuberculosis remains a leading cause of human mortality. The emergence of strains of Mycobacterium tuberculosis, the causative agent, that are resistant to the major frontline antitubercular drugs increases the urgency for the development of new therapeutic agents. Sequencing of the M. tuberculosis genome revealed the existence of 20 cytochrome P450 enzymes, some of which are potential candidates for drug targeting. The recent burst of studies reporting microarray-based gene essentiality and transcriptome analyses under in vitro, ex vivo and in vivo conditions highlight the importance of selected P450 isoforms for M. tuberculosis viability and pathogenicity. Current knowledge of the structural and biochemical properties of the M. tuberculosis P450 enzymes and their putative redox partners is reviewed, with an emphasis on findings related to their physiological function(s) as well as their potential as drug targets.

Citing Articles

Whole genome sequencing analysis of Mycobacterium tuberculosis reveals circulating strain types and drug-resistance mutations in the Philippines.

Wang L, Lim D, Phelan J, Reyes L, Palparan A, Sanchez M Sci Rep. 2024; 14(1):19602.

PMID: 39179783 PMC: 11344074. DOI: 10.1038/s41598-024-70471-x.

Decoding the Role of CYP450 Enzymes in Metabolism and Disease: A Comprehensive Review.

Abdelmonem B, Abdelaal N, Anwer E, Rashwan A, Hussein M, Ahmed Y Biomedicines. 2024; 12(7).

PMID: 39062040 PMC: 11275228. DOI: 10.3390/biomedicines12071467.

Exploiting Differences in Heme Biosynthesis between Bacterial Species to Screen for Novel Antimicrobials.

Jackson L, Dailey T, Anderle B, Warren M, Bergonia H, Dailey H Biomolecules. 2023; 13(10).

PMID: 37892169 PMC: 10604556. DOI: 10.3390/biom13101485.

Exogenously Scavenged and Endogenously Synthesized Heme Are Differentially Utilized by Mycobacterium tuberculosis.

Donegan R, Fu Y, Copeland J, Idga S, Brown G, Hale O Microbiol Spectr. 2022; 10(5):e0360422.

PMID: 36169423 PMC: 9604157. DOI: 10.1128/spectrum.03604-22.

Roles of cysteine in the structure and metabolic function of CYP142A1.

Lu Y, Sun L, Pang J, Li C, Wang X, Hu X RSC Adv. 2022; 12(38):24447-24455.

PMID: 36128375 PMC: 9425443. DOI: 10.1039/d2ra04257f.

References

GELBARD A, Goldman D . Enzyme systems in the mycobacteria. X. The butyryl dehydrogenase system. Arch Biochem Biophys. 1961; 94:228-35. DOI: 10.1016/0003-9861(61)90034-0. View

Seward H, Roujeinikova A, McLean K, Munro A, Leys D . Crystal structure of the Mycobacterium tuberculosis P450 CYP121-fluconazole complex reveals new azole drug-P450 binding mode. J Biol Chem. 2006; 281(51):39437-43. DOI: 10.1074/jbc.M607665200. View

McLean K, Warman A, Seward H, Marshall K, Girvan H, Cheesman M . Biophysical characterization of the sterol demethylase P450 from Mycobacterium tuberculosis, its cognate ferredoxin, and their interactions. Biochemistry. 2006; 45(27):8427-43. DOI: 10.1021/bi0601609. View

Gordon S, Brosch R, Billault A, Garnier T, Eiglmeier K, Cole S . Identification of variable regions in the genomes of tubercle bacilli using bacterial artificial chromosome arrays. Mol Microbiol. 1999; 32(3):643-55. DOI: 10.1046/j.1365-2958.1999.01383.x. View

Taniguchi H, Aramaki H, Nikaido Y, Mizuguchi Y, Nakamura M, Koga T . Rifampicin resistance and mutation of the rpoB gene in Mycobacterium tuberculosis. FEMS Microbiol Lett. 1996; 144(1):103-8. DOI: 10.1111/j.1574-6968.1996.tb08515.x. View

Hampshire T, Soneji S, Bacon J, James B, Hinds J, Laing K . Stationary phase gene expression of Mycobacterium tuberculosis following a progressive nutrient depletion: a model for persistent organisms?. Tuberculosis (Edinb). 2004; 84(3-4):228-38. PMC: 3195342. DOI: 10.1016/j.tube.2003.12.010. View

Bruggemann R, Alffenaar J, Blijlevens N, Billaud E, Kosterink J, Verweij P . Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents. Clin Infect Dis. 2009; 48(10):1441-58. DOI: 10.1086/598327. View

Zanno A, Kwiatkowski N, Vaz A, Guardiola-Diaz H . MT FdR: a ferredoxin reductase from M. tuberculosis that couples to MT CYP51. Biochim Biophys Acta. 2005; 1707(2-3):157-69. DOI: 10.1016/j.bbabio.2004.11.010. View

Milano A, Pasca M, Provvedi R, Lucarelli A, Manina G, de Jesus Lopes Ribeiro A . Azole resistance in Mycobacterium tuberculosis is mediated by the MmpS5-MmpL5 efflux system. Tuberculosis (Edinb). 2008; 89(1):84-90. DOI: 10.1016/j.tube.2008.08.003. View

10.

Sassetti C, Boyd D, Rubin E . Genes required for mycobacterial growth defined by high density mutagenesis. Mol Microbiol. 2003; 48(1):77-84. DOI: 10.1046/j.1365-2958.2003.03425.x. View

11.

Poole K . Multidrug efflux pumps and antimicrobial resistance in Pseudomonas aeruginosa and related organisms. J Mol Microbiol Biotechnol. 2001; 3(2):255-64. View

12.

Bhatt A, Fujiwara N, Bhatt K, Gurcha S, Kremer L, Chen B . Deletion of kasB in Mycobacterium tuberculosis causes loss of acid-fastness and subclinical latent tuberculosis in immunocompetent mice. Proc Natl Acad Sci U S A. 2007; 104(12):5157-62. PMC: 1829279. DOI: 10.1073/pnas.0608654104. View

13.

Jamil B, Shahid F, Hasan Z, Nasir N, Razzaki T, Dawood G . Interferon gamma/IL10 ratio defines the disease severity in pulmonary and extra pulmonary tuberculosis. Tuberculosis (Edinb). 2007; 87(4):279-87. DOI: 10.1016/j.tube.2007.03.004. View

14.

Ahmad Z, Sharma S, Khuller G . In vitro and ex vivo antimycobacterial potential of azole drugs against Mycobacterium tuberculosis H37Rv. FEMS Microbiol Lett. 2005; 251(1):19-22. DOI: 10.1016/j.femsle.2005.07.022. View

15.

McLean K, Dunford A, Neeli R, Driscoll M, Munro A . Structure, function and drug targeting in Mycobacterium tuberculosis cytochrome P450 systems. Arch Biochem Biophys. 2007; 464(2):228-40. DOI: 10.1016/j.abb.2007.03.026. View

16.

Murphy D, Brown J . Identification of gene targets against dormant phase Mycobacterium tuberculosis infections. BMC Infect Dis. 2007; 7:84. PMC: 1950094. DOI: 10.1186/1471-2334-7-84. View

17.

McLean K, Scrutton N, Munro A . Kinetic, spectroscopic and thermodynamic characterization of the Mycobacterium tuberculosis adrenodoxin reductase homologue FprA. Biochem J. 2003; 372(Pt 2):317-27. PMC: 1223410. DOI: 10.1042/BJ20021692. View

18.

Balding P, Porro C, McLean K, Sutcliffe M, Marechal J, Munro A . How do azoles inhibit cytochrome P450 enzymes? A density functional study. J Phys Chem A. 2008; 112(50):12911-8. DOI: 10.1021/jp802087w. View

19.

Mougous J, Green R, Williams S, Brenner S, Bertozzi C . Sulfotransferases and sulfatases in mycobacteria. Chem Biol. 2002; 9(7):767-76. DOI: 10.1016/s1074-5521(02)00175-8. View

20.

Gao Q, Kripke K, Arinc Z, Voskuil M, Small P . Comparative expression studies of a complex phenotype: cord formation in Mycobacterium tuberculosis. Tuberculosis (Edinb). 2004; 84(3-4):188-96. DOI: 10.1016/j.tube.2003.12.013. View